Patient characteristics at screening examination in the placebo and pegylated interferon α (PegIFN) groups
| PegIFN | ||||
|---|---|---|---|---|
| 0.5 µg/kg (n = 19) | 1 µg/kg (n = 21) | Placebo (n = 20) | p Value | |
| Values are mean (SD) unless otherwise indicated. | ||||
| 5-ASA, 5-aminosalicylate. | ||||
| Sex | 0.985 | |||
| Males (n (%)) | 9 (47.0) | 11 (52.4) | 10 (50.0) | |
| Females (n (%)) | 10 (53.0) | 10 (47.6) | 10 (50.0) | |
| Age (months) | 36.90 (13.19) | 40.90 (10.84) | 46.95 (14.43) | 0.053 |
| Weight (kg) | 68.38 (12.48) | 70.00 (13.31) | 71.82 (17.39) | 0.756 |
| Duration of disease (months) | 107.3 (64.11) | 106.88 (71.83) | 142.90 (132.01) | 0.867 |
| Prestudy steroid therapy (n (%)) | 6 (31.6) | 9 (42.9) | 5 (25.0) | 0.452 |
| Prestudy azathioprine therapy (n (%)) | 2 (10.5) | 3 (14.3) | 3 (15.0) | 0.879 |
| Prestudy 5-ASA therapy (n (%)) | 15 (78.9) | 19 (90.5) | 15 (75.0) | 0.325 |
| Topical 5-ASA treatment | 4 (21.1) | 2 (9.5) | 3 (15.0) | 0.639 |
| Localisation of inflammation | 0.604 | |||
| Sinistral (n (%)) | 13 (68.4) | 12 (57.1) | 14 (70.0) | |
| Pancolitis (n (%)) | 6 (31.6) | 9 (42.9) | 6 (30.0) | |